Raising Capital with MTPConnect and Wholesale Investor

Are you developing a medical science innovation and need funding for your venture? 

MTPConnect and Wholesale Investor are collaborating on a dedicated capital engagement program designed for life science companies looking for private investment. 

Wholesale Investor Co-Founder and Managing Director Steve Torso is behind one of the largest capital raising platforms in Australia, and he joins the podcast to talk about how the MTPConnect Investor Ready program can help life science companies develop an investor network, build a skill base in investor communications and avoid some of the pitfalls when engaging with investors.

He covers what to expect at our upcoming inaugural Life Science Investor Day as part of Wholesale Investor’s Emergence 2026 conference, which will bring together ASX-listed innovators, breakthrough private companies, and global investors driving the future of health, diagnostics, and therapeutics. 

To find out more about the MTPConnect Investor Ready program and to register your interest, visit our website or contact Steve Torso. There are limited places still available. 

Chapters

• 0:01 Welcome And Acknowledgement Of Country
• 0:36 Program Overview And Guest Intro
• 1:24 Why Capital Raising Needed A Rethink
• 2:32 Building Capital HQ And Always‑On Deal Rooms
• 4:37 Funding Shifts And Targeting HNW Investors
• 6:06 Designing The Investor Ready Program
• 8:13 Life Sciences Investor Day: Focus And Format
• 10:56 What It Means To Be Investor Ready
• 14:08 Crafting Narrative for Investors
• 17:02 Educating Investors And Value Inflection Points
• 19:02 Matchmaking Wins And Long‑Term Impact
• 20:51 Life Sciences Investor Day at Emergence 2026
• 23:14 Tips for Making the Most of Your Presentation to Investors
• 27:36 Investor Ready Program: Using Capital HQ Across The Journey
• 29:23 How To Get Involved And Next Steps
• 31:50 Closing, Dates, And Call To Action

Transcript

Natalie Vella: 0:01

This is the MTP Connect podcast, connecting you with the people behind the life-saving innovations driving Australia's growing life sciences sector from bench to bedside for better health and well-being. MTP Connect acknowledges the traditional owners of country that this podcast is recorded on and recognises that Aboriginal and Torres Strait Islander peoples are Australia's first storytellers and the holders of first science knowledge.

Caroline Duell: 0:33

Welcome to the podcast. I'm Caroline Duell. Are you developing a medical science innovation and need funding for your venture? MTP Connect and Wholesale Investor are collaborating on a dedicated capital engagement program designed for life science companies looking for private investors. Steve Torso is the co-founder and managing director of Wholesale Investor, the largest capital raising platform in Australia. We take a look at how the MTP Connect Investor Ready program can help companies develop an investor network and build a skill base in investor communications. And Steve shares some tips for success and the pitfalls to avoid.

Steve Torso: 1:18

Thanks, Caroline.

Caroline Duell: 1:19

What's the inspiration behind your capital raising platform wholesale investor?

Steve Torso: 1:24

We've been in this space since 2008. We initially started out as a magazine and then sort of 2012 we got rid of the magazine and then we started focusing on online to offline. And so we did have a website and all that sort of stuff, but as the sort of years went on, I realized that capital raising wasn't quite what I thought it was, which was sort of explained to me and what you sort of read everywhere, which is basically a process of sending out a pitch deck or sending out an IM and then waiting for an investor to come back with a yes or a no. It was a little bit more, you know, sort of um nuanced than that, in that there was more of an engagement process. And I realized that unless you can actually have a centralized sort of source of truth around your capital raising, it's actually very difficult. And every time you go to raise money, you're basically starting the process from the start again. So it was a combination of my own experience when I had investor uh InvestTech becoming an investor in my business, and I realized that I wasn't ready, I wasn't prepared. And, you know, so I basically started designing the product in what I was experiencing from a capital raise perspective. And then I started using the product to, you know, it's around 2019 to start raising for my own business. And then that's sort of where the whole sort of capital HQ come from is I started building it to basically make my life easier when raising capital. And life is never easy when you're raising capital. So it was just more about how do I do this and just keep on creating efficiencies in the process. And I was just fortunate enough that I could also build a software tool that could assist with that as well.

Caroline Duell: 3:02

So tell us a little bit about the what the capital HQ concept is.

Steve Torso: 3:07

The three parts that I think about it is that one, um, you know, providing access to investors and being able to see sort of who is in an ecosystem, I think is sort of a key part of that. The second part is streamlining and simplifying the process. And then the third part is removing friction from the process. So the only way you could do that is if you think about it from both sides. If you think about it, okay, what's an investor's experience when they come across a company? Basically, typically it's normally just a wall of information. So it's like, well, then how do you think about what are the key parts that you you speak to that get an investor's attention, you know, about an opportunity? And then likewise from the founder side, when you're raising capital, it is just so frustrating saying the same thing over and over again, answering the same questions. In fact, one of my mentors said it best. He goes, when you're raising capital, you just feel like you're the chief repeating officer. You know, you're just saying the exact same thing. So it's like, well, how can you have and also I remember my frustration in that I was having these calls and I felt like it wasn't that the deal room itself wasn't actually working for me when I wasn't pushing it. Where the way I sort of think about now is as how as I have how do I have it in an always on state so that if existing investors want to come back to it a different time, or if potential investors want to come back or shareholders, et cetera, it basically can be in that always on state for the process. So it's there's a whole bunch of things which also align, like in the design of it, align with my belief around the thesis of sort of capital raising, which has become more and more prominent now for many life science companies, just given that you know, over the last couple of years, you've seen you know the ASX make it more and more difficult for sort of earlier stage companies to list with their sort of changing of requirements in sort of 2022 and 2023. And then likewise at that time there's been a corresponding sort of you know introduction of so many different grants that have been made available. But you realize now that, you know, a lot of the state and sort of federal government budgets are are under pressure, and you just sort of have that fear that, you know, what if they do start sort of cutting those programs? So, you know, it's sort of I suppose my thesis, you know, is that if you're targeting high net worth and family offices, which many companies will have to because there's only a handful of sort of VCs, and there's a different approach in how you do that. That's where I've spent a lot of my time trying to understand what is the art and I suppose the science of raising money.

Caroline Duell: 5:44

Yeah, so that's that's what we're going to talk about today. It's really this focus on the life sciences sector and startups and small to medium enterprises that are looking for backing and an opportunity that MTP Connect and Wholesale Investor have worked up really for our life sciences sector. Maybe you could talk to us a little bit about that.

Steve Torso: 6:06

So those things I just mentioned before, I suppose they sit at the foundation of sort of why you know this sort of program became available. For me, I got the life science bug in 2009. We worked with uh Q Biotics and we've obviously worked with a lot of life science companies, ranging from you know 4D medical when they come out of sort of Monash University. Likewise, you know, I've got Recy Pharmaceuticals coming to mind. We've been there with sort of Imogen as they've gone through their various sort of ups and downs, etc. So I understand the nature of how hard it is with raising capital, but also I understand that the majority of life science companies who come across, they've all been the majority being funded, you know, in the early days by high networks and family officers. So that's where sort of this conversation between us was really about how do we put a spotlight on the what great work's happening in life sciences, because you guys do a great job of communicating the success about what people are doing and where they're at, but very few other people really get to get a real big feel for how many great success stories and all the incredible things that people are building sort of in that space. And then when you have buzzwords like AI come over and you start to see all those start to dominate, it's like, well, you know, how do you sort of then capture investors, uh investors' attention? So that's where we sort of started designing this whole program around how do you create something where it puts a spotlight on it? It allows the sort of CEOs and the people behind the business to tell the story behind the business, but also the technology as well. And then how do you, I suppose, create the story for the companies where it's simple, it's more personal, it's more humanized, and much more engaging to involve people in. So, you know, as I said, it's it's multi-step in the way in which we've thought about it. But my my biggest hope is that sort of by the time we sort of finish this program and by the time we've finished the the sort of life sciences investor day, that people share the same enthusiasm that I have, you know, after sort of chatting with all the various companies that will be participating.

Caroline Duell: 8:13

And what you're talking about really is um your wholesale investor network, you've built up a huge ecosystem of like 45,000 private investors, high net worth investors, who tap into a number of different opportunities throughout the year for you know to invest in different sectors. Um this is the first time you've actually looked at doing a specific uh life science investor day. It's due to happen next um next year in February. Um, tell us about that opportunity.

Steve Torso: 8:46

I'm a big believer in concentration of energy. And so whilst we've always worked with you know life science companies, the the reality is that when we've done it, there's we've basically had them in amongst all sort of other types of opportunities. So, for example, we could have had like an ag tech opportunity or a you know renewable energy opportunity or a fund, for example. And so, you know, whilst we would always have you know life science companies presenting, there was never that one time where it's like just life science. And so that way, you know, you know, like for every company that's presenting, they know that every single person in that room is there to listen to life sciences, listen to medical device, listen to healthcare opportunities and there to engage. And I know also from a psychology factor as well, in building up something like this, when you're promoting it, it's so much easier when you're promoting something sector focused, you to attract likewise all the investors that have an interest in that area, even though they won't be as technical as probably one every CEO wants them to be. You know, they want to understand the science. They want, you know, the fact they've got an interest is a great starting point. And you find that the way it works with sort of high net worse is they could say they they could go through all the sessions they want and say, Oh, don't don't invest in something you don't understand. Don't do the reality is, you know, I've had so many times where investors said, I only invest in this type of deal. And then you see that they've gone and invested into a life science company or in a biotech because they've got some sort of personal connection. So, you know, if we do this, do this right, we're basically helping the companies articulate the humanized story of what they're doing. We're helping them sort of communicate what is the critical pathways or sort of, I suppose, inflection points in the valuation of their business, and then helping them take the investor uh along for the journey as well. And then obviously the outcome is we want them to participate.

Caroline Duell: 10:47

So the whole idea is to try and help life science companies get investor ready. What do you need to be investor ready? Because you need more than a website, right?

Steve Torso: 10:56

Investor ready has become like I suppose a term that people like to use. I sort of frame it slightly because the hardest part is I I just don't feel like you're ever really investor ready, no matter who your business is. So the way I think about it is it's more about you're you're articulating what you're doing in a way that engages investors. So you're gonna do all your stuff like preparing your preparing your deal room, getting your information, getting IP, getting what all the all the stuff that you expect. That's sort of when someone's already interested. That's when that becomes really important. The question is, is how do you get someone interested? So I suppose the part I focus on is what is the narrative that that a technical business is going to sell to high net worth and family obviously investors that makes them want to know more. So in marketing, you're taught effectively there's three stages of someone buying something. There's the awareness of it, then there's a consideration, and then there's a decision. Most people, when they're raising money, they think about it like, hey, you're aware of me, right? And you should make a decision, you know. And unfortunately, that consideration part is the part that sort of people forget, you know, in that. So, you know, that that that investor ready part I talk about is more around how do you communicate what is your three to seven-word hero text about what you're doing that is relevant to high net worth and family offices. You know, what is that seven? Because effectively you get seconds of headspace with someone before they're deciding if they're interested. You know, there's another acronym in in marketing they call awareness, interest, desire, action, right? And you only have seconds to capture someone's awareness. So the hardest part for every, you know, every life science founder or medical device founder is just sitting there thinking that I spend my life 24-7 thinking about this, working on it, solving problems. But the truth is the person you're going to be pitching it to gives you seconds of headspace to decide if they're interested. So that's why I always start with what is that headline hero text? The next part that I really love to go into is how do you succinctly summarize that sort of problem solution statement? So, you know, do you know how to identify the problem? What we do is identify the solution. And then the next part that I love is that what are the investment highlights? And investment highlights can also get misconstrued and to think about, oh, I need to sell what's revenue, what's, you know, it's that that can be a part at some stage, but at this early stage, it's really about, you know, who is the team? What is the team's been there, done that experience? How can that be explained in one to two lines? That when an investor sees it, they think that's interesting. You know, I think that's the I think that's the key word you're going for is you you're trying to get into the headspace of investors where they look at what you're doing and think, that's interesting. I want to know more. So headline hero text, then problem solution statement, and then the next one is those highlighting of those investment highlights. So teens been there, done that experience. Who has backed you to date? You know, and what is what form has that been in? You know, have you put in a significant amount of money yourself into the actual business? That's always a good sign. Have you had investors already put money, you know? For example, one of the companies I spoke to had, you know, the Mayo Venture Fund put money into them. That's interesting, right? Or have you had private high net worth that uh sort of known put money in? Even if it's 25k, 50k, 100k, it doesn't matter. The fact they invested is a signal for other investors. And then have you received what grants have you received? Because often the grant process sort of goes through a lot more you know technical depth as far as what you're actually doing before you've actually received funds. And if there's bigger investment groups, fantastic. So whether they be personal investors or bigger investors, highlight that. So they're the sort of two starting ones. And then the next one is is well, where are you actually at? You know, are you you know going through your trial process? Have you done some of the early data work, you know, etc.? Where where is that, you know, what have you got to do? Yeah, correct.

Caroline Duell: 15:21

Are you close to getting regulatory approval or you know, are you just starting out with your first clinical trial? Like all of those sort of milestones they can position companies in a particular in a particular way.

Steve Torso: 15:33

And did you get any partnerships with that? You know, is do you have any partnerships with hospitals, research institutes, you know, et cetera, that you can sort of speak to? Because again, once again, it's all leveraging off brands that would be known, you know, like whether it be, you know, I'm just trying to think of the name, but there was like various research institutes that sort of got mentioned in in a lot of the conversations, or various hospitals that got mentioned. That becomes about yeah, correct. So so there's some of the things like when I think about investment ready, I think about marketing, I suppose marketing marketing ready, you know, for for for going out to sort of high net worth and family offices.

Caroline Duell: 16:13

And what do you think about the need to educate investors about investing in the life sciences sector? Because it's it's a different game to perhaps other technology. It's it might be a longer game, for instance, um, depending on what it is, whether it might be a therapeutic versus a medical device or um a diagnostic or something like that. But yeah, as part of the program that that MTP Connect is running with um wholesale investor, there's also some uh investor education as part of that. What does that look like?

Steve Torso: 16:49

So when you started mentioning that, I thought straight away we had a keynote from Hashan DeSilva from KPRX at our Emergence Conference, and it was one of the best educations about where he likes to invest in into life science, you know, in life science companies. But I think the the education is a key part because if you hear how investors explain how they're trying to assess opportunities, you can then also reframe your narrative to align with that. So for example, you know, when you're when you're, you know, you always got to think about in your decks about use of funds. So you're raising X amount of million to go and do X trials or you know, basically get to next sort of data point or prototyping or first products or go to market strategy, et cetera. Well, I suppose in their mind, they're trying to assess how you're using that money, right? And this is where invest and this is where it's helpful to understand that that investor education part, how you're using that money and how it correlates with a value inflection point if you achieve that milestone. So many companies will tell me about oh, we want to do this because we want to get our trial to you know this next stage or you know, phase two or whatever it is. So effectively, if that's the case, what does that actually mean? If you get it to that, how does that change the valuation profile of the business? What opportunities does that mean? You know, what companies are there that are in your sort of simulator area where you can look to as references? So that investor education is important because however they receive their education, you need to understand that they will also then want to hear opportunities communicated, then in the way that they have understood what to be looking for.

Caroline Duell: 18:45

You've worked with so many companies over the years. You know, you've been doing this for about 14 years now.

Steve Torso: 18:51

It's actually our this October was our 17th birthday, which is you know, it's comes out when it comes out of your mouth. That's it's like when you get older, you only realize your age when it comes out of your mouth.

Caroline Duell: 19:02

It must be um rewarding to be sort of matchmaking these investment opportunities for companies and and seeing you know company exits and you know that type of success. How do you feel about being the matchmaker?

Steve Torso: 19:17

Ultimately, like I'm I realize that we play a small role, but it's a high value role. I think where you get satisfaction is from you know seeing what you've actually assisted with in the early days then sort of come to fruition down the track. Like 40 medical comes to mind. You know, I said working with them as a siege stage company, sort of coming out of Monash University and speaking with Andreas, you know, just as he was going into IPO and just telling me how important it was those 50, 100k, 200k checks were sort of in those early days compared to how much easier it was when he was going to IPO and he was being offered 5 million, you know, 2 million, 10 million from different instants. That's that's pretty rewarding. You know, it doesn't really get acknowledged, you know, too much, but that's sort of a very rewarding fact. Or someone like Cube Ice said, you know, we are coming out the back end of the GFC and they needed to raise 2 million and seeing our network sort of deliver on that 2 million, then sort of 2021 seeing TDM go in for 50 million, you know, in into the company, and now they're sort of making their pathway sort of more, you know, towards an exit as well. That's pretty cool. Or, you know, looking at some of the, you know, some of the life science companies like a Recce, you know, go through their journey through all their different sort of stages and like it's very rewarding. It's also you realize all your anti-portfolio of what you didn't invest into, but it's it's rewarding to see them hit their goals and and you know that you played a small role sort of in that. I think that's where I get a lot of satisfaction from.

Caroline Duell: 20:51

Tell us about what the Life Sciences Investor Day is going to look like in February. What's involved in a wholesale investor day?

Steve Torso: 20:59

So the Life Science Investor Day is part of our bigger conference called Emergence. So Emergence is the biggest thing that we do each year. We last year, I think we had somewhere between 750 to 1,000 come along to it. This year, obviously, you know, no different than everyone else. I want to make it bigger. Um, so it's a really simple format, and we typically have like three sort of panel sessions, and you know, with that, we have different investment groups provide their sort of investment thesis about how they're sort of looking to invest. And you know, you typically have a couple keynotes, but the main part is that we we provide various networking sort of sessions, both in the morning, during the event, and then sort of in the afternoon, so that you know investors can go around and chat to the various companies that are being featured. And then each company gets their own sort of eight-minute presentation as well. So it's not just about having a trade table and being at it, you actually get to present to investors your opportunity and effectively they can then sort of come up and engage with you. But the the key part to how we've worked together on this is that you know we're going to start doing all the recording of CEO interviews, we're gonna be doing articles on the companies involved. Um, it within our Capital HQ software. We've actually got a conferencing component in there. So the companies that are presenting can access the investors in in the conference as well and can message them directly and invite them to come and chat with them. Plus, we're also recording everyone's presentation, so we'll make that available to them afterwards. We'll be doing interviews at the event as well. So all this sort of stuff becomes all the different touch points that you can sort of build, you know, in the process of your own capital raising and you can share across your LinkedIn media, et cetera. So my look, basically, my hope is that thousands of people get, you know, a whole bunch of content around. Oh, and we also live stream as well, which is the other component. But my the big hope is is that just so many different touch points around life sciences and medical device and healthcare is created for us across the next few months and where bring a lot more investor interest sort of into the area.

Caroline Duell: 23:03

I suppose this, you know, what we've termed a tight funding environment. Yeah. Can you share any sort of capital insights that are relevant for the life sciences sector?

Steve Torso: 23:14

Yeah, I'll I would just say like capital raising is frustrating at the best of times, except for that beautiful spot of late 2020 and uh early and 2021. But you know, I would say focus on engagement of investors. Instead of focusing on just raising from investors, focus on the engagement component. Let them sort of, you know, said that going back to that awareness, consideration, decision part, spend let them spend time in that consideration part, but make it easy for them to spend time in that consideration part. So have things like your frequently asked questions already prepared. You know, so all the questions that other investors have previously asked you, don't make them ask it to you again. Have it ready for them, sort of in you know, in your deal room. Um have a video that's really easy, that's very humanized about sort of what you're doing, where you're at, you know, as and obviously we do that as part of our CEO interview. And and then also there's gonna be a key part. There's a key part of raising money where you've got interest in what you're doing and you're you're massively frustrated because you've got this interest and then no one's converting. And it's at that stage, that is the most crucial point, is where you've got to have the courage to put a deadline in place. By human nature, we typically work towards deadlines, manufactured or real, everyone works towards deadlines like an IPO. An IPO puts a deadline on something and makes everyone move towards that deadline. And so effectively, when you have that, when you have that sort of feel that momentum, you switch on a deadline and then you crank up the activity. So you crank up things like information sessions, crank up sort of doing more one-to-one conversations, boardroom sessions, etc. You know, it's just leaving it out there. They've got to feel those multiple touch points. So focus on the engagement system and then also, you know, I've called it capital engagement system, but and then also even when you close your raise, keep communicating like there's a raise coming up. So the best lesson I learned was from a journalist where he said, uh, companies only want to speak to me when they're going to raise money, and then when when I'm done, they never speak to me again. And that can also happen, you know, with companies. So, you know, that just focus on that engagement, make sure, and every time you send out an investor update about where, you know, about an announcement or whatever it is, try and do at least every month to two months. So that way they feel like you're not out of sight, out of mind. So try and stay top of mind, focus on engagement, and content plays a role. And content's so much easier to create now with AI and make sure it's human-centric in the way in which you communicate. Of course, your instant investors and you're more technical investors, you may want to have different sort of communications for them. But if you're dealing with high net worth and family officers, you know, make sure it's sort of very, very humanized.

Caroline Duell: 26:16

Yeah, so it's you've really got to think about that investor strategy in terms of the continuing that connection and that communication.

Steve Torso: 26:23

Yeah, and running a process and actually running it as a process. But then I said, just remember that key inflection point where you've got lots of interest and no one's converting. That's when you've got to switch on a deadline. And that's the scariest thing to do because you know you could look like a failure.

Caroline Duell: 26:39

What can go wrong? Where do companies go wrong when they're approaching investors?

Steve Torso: 26:44

Firstly, thinking that they'll understand the science. Number one. Number two is treating investors like a transaction. Right. As I said, all of us as humans, we want to feel, you know, like we've got some sort of connection. I think they would be the the two biggest things, you know, and and then also not actually running in process. Like I'd say would be the three. So typically what happens with a capital raise is that you know, you start out the raise, you're very because to get your energy up, you get really bullish, really confident, and you start out with, I want to raise five million from five investors, right? And then as you find out that that's not as realistic as what you thought, then you suddenly start to think, you know, so you've got to be confident, but not overconfident. Humanize the the process and actually run, you know, to a process and just make sure you factor in sort of multiple touch points in it.

Caroline Duell: 27:40

So one of the um opportunities through the program that we're running that we've asked companies to um sign up for, which is kicking off in November, as part of that package, they get access to your um capital HQ program.

Steve Torso: 27:56

The idea is that so they don't have to bother about setting up other data rooms or setting up other, you know, effectively they can create multiple rooms, they can have a high-level room to engage investors in, they can have a deeper data room if they want to, they can even use create a room for their their board meetings, you know, if they want to for the earlier, for the earlier sort of companies, you know, other down the track they can get sort of official board software, etc. But yeah, it's more like I said, it's just taking a long-term approach to the raise and appreciating that as a life science company, medical device company, capital is going to be a consistent requirement going forward. So if an investor can come into your room three years from now and they can see every milestone, every progress that you've done, every announcement that you've made, and every announcement you've delivered on, you don't have to answer the question about the history of your business because it's all summarized in one area. And instead of asking you all those questions, they can spend that time with your room. So, you know, I found for me that sort of cut down me having to spend four to six hours with every investor down to 30 minutes to an hour. I know there's going to be other opportunities that companies will want to be involved in, sort of whether it be our events or dedicated emails or whatever it may be. But the core foundation is if they're already set up, they've got that sort of, you know, get ready, stay ready, always be raising sort of mindset, then they're ultimately just setting themselves up for success long term anyway.

Caroline Duell: 29:22

Brilliant. Tell us how companies can find out more about wholesale investor and and your Capital HQ platform.

Steve Torso: 29:30

They can obviously reach out to you guys, or uh, or they can just come to wholesaleinvestor.com and uh you know just basically sort of you know register on one of the sort of capital raising pages and you know come and chat to us and learn more.

Caroline Duell: 29:45

You run a lot of programs. I mean, every week you've got seminars and webinars, and you have a lot happening um on your platform. Things are up on YouTube, you can kind of see how how you roll at wholesale investor.

Steve Torso: 30:00

The thing I'm most excited about is I want people to feel how I felt after two weeks of chatting to, you know, chatting to various sort of life science and medical device companies. And the easiest takeaway that I've been saying to people is I'm very bullish about Australian innovation after having all these conversations. So I just hope that, you know, when we sort of get the feedback from attendees of that day, they feel the same way that I do. And if we've set everyone up right and done all the right promotion and helped everyone tell their stories right, etc., then they should feel that.

Caroline Duell: 30:34

Well, it's only a few months away now, the the investor day. So we're starting to work with companies that have signed up for the program. And um it's really exciting.

Steve Torso: 30:43

It's very exciting. I said, I think I think when this is all when we're sort of finished, this, I think, you know, I said for me on the on the personal side, this has been one of the most fun things that I I've enjoyed. Ultimately, you know, it will be on the day where I said I I just hope that the companies, you know, when they sort of finish their presentation, they finish the engagement across even across the rest of the conference as well, just going around and sort of meeting with everyone. But they also feel bullish about investor interest in Australian life science companies as well. Because I know that's been a common theme along a lot of companies, as they think, oh, Australian investors just don't understand us, or Australian investors don't back life science, they just want to back software. And I just don't think that's the case. So there's too many investors that have invested into you know listed list, you know, if you think about the share registries of all the public unlisted companies and listed companies, it's littered with high net worth and family offices.

Caroline Duell: 31:38

Lots of opportunity out there, so we're just trying to make that happen.

Steve Torso: 31:42

Correct. You know, if you if you aren't able to make the program because we've sort of finished the allocations and sort of at least come along and feel the energy of the day itself.

Caroline Duell: 31:53

Thank you, Steve, for coming on the MTP Connect podcast.

Steve Torso: 31:57

Thanks, Caroline. I appreciate the interview.

Caroline Duell: 31:59

That was Wholesale Investor's Steve Torso joining us from Sydney to talk about raising capital and the new MTP Connect Investor Ready program. The program culminates with the inaugural Life Sciences Investor Day, which is part of the Emergence 2026 conference, to be held on the 18th of February in Sydney. If you want to get involved, check our website for details or contact Wholesale Investor. You've been listening to the MTP Connect podcast. This podcast is produced on the lands of the Wurundjeri people here in NAARM, Melbourne. Thanks for listening to the show. If you love what you heard, share our podcast and follow us for more. Until next time.